Abridge Secures $150M Series C Funding to Transform Clinical Documentation with Generative AI.
Abridge is revolutionizing the way clinical documentation is handled in the healthcare sector.
Company Name: Abridge
Location: Pittsburgh, PA
Sector: Generative AI for Clinical Documentation
Funding Details: Received an additional $150M in Series C funding, led by Lightspeed Venture Partners. Other participants included Redpoint Ventures, IVP, Spark Capital, Union Square Ventures, Bessemer Venture Partners, Wittington Ventures, Mass General Brigham Artificial Intelligence and Digital Innovation Fund (AIDIF), Kaiser Permanente Ventures, and CVS Health Ventures. This comes after a $30M Series B round just four months prior.
Purpose of Investment: To expand the team and develop foundation models utilizing extensive multimodal healthcare data.
Leadership: Dr. Shiv Rao, CEO and Founder
Product: Abridge's platform enhances clinical documentation by converting patient-clinician conversations into structured clinical notes in real-time, integrating deeply with Electronic Medical Records (EMRs). Their technology, evaluated in 14 languages and supporting many more, aims to improve documentation efficiency and clinician focus on patient care. The “Linked Evidence” feature uniquely maps portions of summaries to the evidence in the source transcript, enhancing transparency and reliability.
About Company: Abridge is revolutionizing the way clinical documentation is handled in the healthcare sector. By leveraging generative AI, Abridge's platform aims to streamline the documentation process, enabling clinicians to dedicate more attention to patient care. The company's technology not only improves the efficiency of creating clinical notes but also integrates evidence mapping for enhanced note reliability. With a new partnership with Yale New Haven Health System, Abridge is set to significantly reduce the cognitive burden on clinicians, marking a significant step forward in healthcare documentation.
